LAG-3分子在非小细胞肺癌中的研究进展
Research Progress of LAG-3 Molecule in Non-Small Cell Lung Cancer
DOI: 10.12677/ACM.2022.126865, PDF,   
作者: 王思帆：青海大学，青海 西宁；张易青*：青海大学附属医院病理科，青海 西宁
关键词: 淋巴细胞活化基因-3；T淋巴细胞；免疫检查点；非小细胞肺癌；Lymphocyte-Activation Gene-3； T Cell； Immune Checkpoint； Non-Small Cell Lung Cancer
摘要: 免疫检查点抑制已经被证明可以成功地重新激活针对肿瘤相关抗原的T细胞反应，从而显著延长各种实体瘤患者的总生存期。其中，细胞毒性T淋巴细胞蛋白4 (CTLA-4)和程序性细胞死亡蛋白1 (PD-1)在肿瘤免疫逃逸中起关键作用，是公认的癌症免疫治疗靶点。然而，PD-1和CTLA-4在肿瘤治疗中的研究达到了不同程度的瓶颈。因此，在肿瘤微环境研究中寻找可以替代的治疗靶点成为目前研究的热点问题。而淋巴细胞活化基因-3 (LAG-3)通过与配体的细胞外结构域结合，负向调节T淋巴细胞，从而避免T细胞过度活化引起的自身免疫。故LAG-3现在被认为是新一代的免疫治疗靶点。本文综述了LAG-3在非小细胞肺癌中的研究进展，为进一步研究LAG-3提供参考。免疫检查点LAG-3在癌症发展中起着至关重要的作用，可能会用于未来的癌症治疗临床实践。
Abstract: Immune checkpoint inhibition has been shown to successfully reactivate t-cell responses to tu-mor-associated antigens, thereby significantly prolonging overall survival in patients with a variety of solid tumors. Among them, cytotoxic T lymphocyte protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) play key roles in tumor immune escape and are recognized as cancer im-munotherapy targets. However, the research of PD-1 and CTLA-4 in tumor therapy has reached dif-ferent degrees of bottleneck. Therefore, it has become a hot topic to find alternative therapeutic targets in tumor microenvironment research. While lymphocyte activation gene-3 (LAG-3) nega-tively regulates T lymphocytes by binding to the extracellular domain of ligand, thus avoiding au-toimmunity caused by T cell overactivation. Therefore, LAG-3 is now considered as a new immuno-therapy target. This paper reviews the research progress of LAG-3 in non-small cell lung cancer, and provides reference for the further study of LAG-3. Immune checkpoint LAG-3 plays a critical role in cancer development and may be used in future cancer treatment clinical practice.
文章引用：王思帆, 张易青. LAG-3分子在非小细胞肺癌中的研究进展[J]. 临床医学进展, 2022, 12(6): 5990-5997. https://doi.org/10.12677/ACM.2022.126865

参考文献

[1] Galluzzi, L., Vacchelli, E., Bravo-San Pedro, J.M., Buqué, A., Senovilla, L., Baracco, E.E., Bloy, N., Castoldi, F., Abas-tado, J.P., Agostinis, P., et al. (2014) Classification of Current Anticancer Immunotherapies. Oncotarget, 5, 12472- 12508. [Google Scholar] [CrossRef] [PubMed]
[2] Fang, Z., Han, H. and Liang, L. (2019) Progression in Chi-meric Antigen Receptor T (CAR-T) Cell Therapy of Solid Tumors: A Review. Chinese Journal of Cellular and Molecu-lar Immunology, 35, 944-948.
[3] Krishnamurthy, A. and Jimeno, A. (2018) Bispecific Antibodies for Cancer Thera-py: A Review. Pharmacology & Therapeutics, 185, 122-134. [Google Scholar] [CrossRef] [PubMed]
[4] Li, X., Shao, C., Shi, Y. and Han, W. (2018) Lessons Learned from the Blockade of Immune Checkpoints in Cancer Immunotherapy. Journal of Hematology & Oncology, 11, 31. [Google Scholar] [CrossRef] [PubMed]
[5] Weinmann, S.C. and Pisetsky, D.S. (2019) Mechanisms of Immune-Related Adverse Events during the Treatment of Cancer with Immune Checkpoint Inhibitors. Rheumatology (Oxford), 58, vii59-vii67. [Google Scholar] [CrossRef] [PubMed]
[6] Zhao, Y., Yang, W., Huang, Y., Cui, R., Li, X. and Li, B. (2018) Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy. Cellular Physiology and Biochemistry, 47, 721-734. [Google Scholar] [CrossRef] [PubMed]
[7] Postow, M.A., Callahan, M.K. and Wolchok, J.D. (2015) Im-mune Checkpoint Blockade in Cancer Therapy. Journal of Clinical Oncology, 33, 1974-1982. [Google Scholar] [CrossRef] 
[8] Burugu, S., Gao, D., Leung, S., Chia, S.K. and Nielsen, T.O. (2017) LAG-3+ Tumor Infiltrating Lymphocytes in Breast Cancer: Clinical Correlates and Association with PD-1/PD-L1+ Tumors. Annals of Oncology, 28, 2977-2984. [Google Scholar] [CrossRef] [PubMed]
[9] Huard, B., Prigent, P., Tournier, M., Bruniquel, D. and Triebel, F. (1995) CD4/Major Histocompatibility Complex Class II Interaction Analyzed with CD4- and Lymphocyte Activation Gene-3 (LAG-3)-Ig Fusion Proteins. European Journal of Immunology, 25, 2718-2721. [Google Scholar] [CrossRef] [PubMed]
[10] Dijkstra, J.M., Somamoto, T., Moore, L., Hordvik, I., Ototake, M. and Fischer, U. (2006) Identification and Characterization of a Second CD4-Like Gene in Teleost Fish. Molecular Immunol-ogy, 43, 410-419. [Google Scholar] [CrossRef] [PubMed]
[11] Triebel, F., Jitsukawa, S., Baixeras, E., Roman-Roman, S., Genevee, C., Viegas-Pequignot, E. and Hercend, T. (1990) LAG-3, a Novel Lymphocyte Activation Gene Closely Re-lated to CD4. Journal of Experimental Medicine, 171, 1393-1405. [Google Scholar] [CrossRef] [PubMed]
[12] Sierro, S., Romero, P. and Speiser, D.E. (2011) The CD4-Like Mole-cule LAG-3, Biology and Therapeutic Applications. Expert Opinion on Therapeutic Targets, 15, 91-101. [Google Scholar] [CrossRef] [PubMed]
[13] Workman, C.J., Dugger, K.J. and Vignali, D.A. (2002) Cut-ting Edge: Molecular Analysis of the Negative Regulatory Function of Lymphocyte Activation Gene-3. The Journal of Immunology, 169, 5392-5395. [Google Scholar] [CrossRef] [PubMed]
[14] Goldberg, M.V. and Drake, C.G. (2011) LAG-3 in Cancer Immunotherapy. Current Topics in Microbiology and Immunology, 344, 269-278. [Google Scholar] [CrossRef] [PubMed]
[15] Iouzalen, N. andreae, S., Hannier, S. and Triebel, F. (2001) LAP, a Lymphocyte Activation Gene-3 (LAG-3)-Associated Protein That Binds to a Repeated EP Motif in the Intracellular Re-gion of LAG-3, May Participate in the Down-Regulation of the CD3/TCR Activation Pathway. European Journal of Immunology, 31, 2885-2891. [Google Scholar] [CrossRef] 
[16] Li, N., Wang, Y., Forbes, K., Vignali, K.M., Heale, B.S., Saftig, P., Hartmann, D., Black, R.A., Rossi, J.J., Blobel, C.P., et al. (2007) Metalloproteases Regulate T-Cell Proliferation and Effector Function via LAG-3. EMBO Journal, 26, 494-504. [Google Scholar] [CrossRef] [PubMed]
[17] Demeure, C.E., Wolfers, J., Martin-Garcia, N., Gaulard, P. and Triebel, F. (2001) T Lymphocytes Infiltrating Various Tumour Types Express the MHC Class II Ligand Lymphocyte Activation Gene-3 (LAG-3): Role of LAG-3/MHC Class II Interactions in Cell-Cell Contacts. European Journal of Cancer, 37, 1709-1718. [Google Scholar] [CrossRef] 
[18] Huard, B., Mastrangeli, R., Prigent, P., Bruniquel, D., Donini, S., El-Tayar, N., Maigret, B., Dréano, M. and Triebel, F. (1997) Characterization of the Major Histocompatibility Complex Class II Binding Site on LAG-3 Protein. Proceedings of the National Academy of Sciences of the United States of America, 94, 5744-5749. [Google Scholar] [CrossRef] [PubMed]
[19] Kouo, T., Huang, L., Pucsek, A., Cao, M., Solt, S., Armstrong, T. and Jaffee, E. (2015) Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells. Cancer Immunology Research, 3, 412-423. [Google Scholar] [CrossRef] 
[20] Dumic, J., Dabelic, S. and Flogel, M. (2006) Galectin-3: An Open-Ended Story. Biochimica et Biophysica Acta, 1760, 616-635. [Google Scholar] [CrossRef] [PubMed]
[21] Mao, X., Ou, M.T., Karuppagounder, S.S., Kam, T.I., Yin, X., Xiong, Y., Ge, P., Umanah, G.E., Brahmachari, S., Shin, J.H., et al. (2016) Pathological α-Synuclein Transmission Initi-ated by Binding Lymphocyte-Activation Gene 3. Science, 353, aah3374. [Google Scholar] [CrossRef] [PubMed]
[22] Visan, I. (2019) New Ligand for LAG-3. Nature Immunology, 20, Article No. 111. [Google Scholar] [CrossRef] [PubMed]
[23] Wang, J., Sanmamed, M.F., Datar, I., Su, T.T., Ji, L., Sun, J., Chen, L., Chen, Y., Zhu, G., Yin, W., et al. (2019) Fibrinogen-Like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3. Cell, 176, 334-347e312. [Google Scholar] [CrossRef] [PubMed]
[24] Goldberg, M.V. and Drake, C.G. (2011) LAG-3 in Cancer Immu-notherapy. Current Topics in Microbiology and Immunology, 344, 269-278. [Google Scholar] [CrossRef] [PubMed]
[25] 马成龙, 沈冬, 孙晓, 关乃富, 孙岳军, 戚春建. LAG-3在非小细胞肺癌细胞中的异位表达及其临床意义[J]. 中国医刊, 2019, 54(9): 1005-1008.
[26] 黄维, 张庆娟, 刘柯, 徐茜, 周美英. 非小细胞肺癌中免疫检查点表达与临床特征及预后的关系分析[J]. 癌症进展, 2019, 17(5): 571-574.
[27] 江露, 吴昌平, 徐斌, 蒋敬庭. 胃癌患者血清中可溶性LAG-3分子的水平及意义[J]. 临床检验杂志, 2014, 32(1): 38-40.
[28] Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., et al. (2010) Tumor-Infiltrating NY-ESO-1-Specific CD8+ T Cells Are Negatively Regulated by LAG-3 and PD-1 in Human Ovarian Cancer. Proceedings of the National Academy of Sciences, 107, 7875-7880. [Google Scholar] [CrossRef] [PubMed]
[29] Okazaki, T., Okazaki, I.M., Wang, J., et al. (2011) PD-1 and LAG-3 Inhibitory Co-Receptors Act Synergistically to Prevent Autoimmunity in Mice. Journal of Experimental Medicine, 208, 395-407. [Google Scholar] [CrossRef] [PubMed]
[30] Maeda, T.K., Sugiura, D., Okazaki, I.M., et al. (2019) Atypical Motifs in the Cytoplasmic Region of the Inhibitory Immune Co-Receptor LAG-3 Inhibit T Cell Activation. Journal of Biological Chemistry, 294, 6017-6026. [Google Scholar] [CrossRef] 
[31] Blackburn, S.D., Shin, H., Haining, W.N., et al. (2009) Coregula-tion of CD8+ T Cell Exhaustion by Multiple Inhibitory Receptors during Chronic Viral Infection. Nature Immunology, 10, 29-37. [Google Scholar] [CrossRef] [PubMed]
[32] Tian, X., Zhang, A., Qiu, C., et al. (2015) The Upregulation of LAG-3 on T Cells Defines a Subpopulation with Functional Exhaustion and Correlates with Disease Progression in HIV-Infected Subjects. Journal of Immunology, 194, 3873-3882. [Google Scholar] [CrossRef] [PubMed]
[33] Phillips, B.L., Mehra, S., Ahsan, M.H., et al. (2015) LAG3 Ex-pression in Active Mycobacterium tuberculosis Infections. The American Journal of Pathology, 185, 820-833. [Google Scholar] [CrossRef] [PubMed]
[34] Butler, N.S., Moebius, J., Pewe, L.L., et al. (2011) Therapeutic Blockade of PD-L1 and LAG-3 Rapidly Clears Established Blood-Stage Plasmodium Infection. Nature Immunology, 13, 188-195. [Google Scholar] [CrossRef] [PubMed]
[35] Chen, N., Liu, Y., Guo, Y., et al. (2015) Lymphocyte Activation Gene 3 Negatively Regulates the Function of Intrahepatic Hepatitis C Virus-Specific CD8+ T Cells. Journal of Gastroenterology and Hepatology, 30, 1788-1795. [Google Scholar] [CrossRef] [PubMed]
[36] Dong, Y., Li, X., Zhang, L., et al. (2019) CD4+ T Cell Exhaustion Revealed by High PD-1 and LAG-3 Expression and the Loss of Helper T Cell Function in Chronic Hepatitis B. BMC Immunolo-gy, 20, Article No. 27. [Google Scholar] [CrossRef] [PubMed]
[37] Erickson, J.J., Rogers, M.C., Tollefson, S.J., et al. (2016) Multi-ple Inhibitory Pathways Contribute to Lung CD8+ T Cell Impairment and Protect against Immunopathology during Acute Viral Respiratory Infection. The Journal of Immunology, 197, 233-243. [Google Scholar] [CrossRef] [PubMed]
[38] Roy, S., Coulon, P.-G., Srivastava, R., et al. (2018) Blockade of LAG-3 Immune Checkpoint Combined with Therapeutic Vaccination Restore the Function of Tissue-Resident Anti-Viral CD8+ T Cells and Protect against Recurrent Ocular Herpes Simplex Infection and Disease. Frontiers in Immunology, 9, Article No. 2922. [Google Scholar] [CrossRef] [PubMed]
[39] Cook, K.D. and Whitmire, J.K. (2016) LAG-3 Confers a Competi-tive Disadvantage upon Antiviral CD8+ T Cell Responses. The Journal of Immunology, 197, 119-127. [Google Scholar] [CrossRef] [PubMed]
[40] Richter, K., Agnellini, P. and Oxenius, A. (2010) On the Role of the Inhibitory Receptor LAG-3 in Acute and Chronic LCMV Infection. International Immunology, 22, 13-23. [Google Scholar] [CrossRef] [PubMed]
[41] Huang, C.-T., Workman, C.J., Flies, D., et al. (2004) Role of LAG-3 in Regulatory T Cells. Immunity, 21, 503-513. [Google Scholar] [CrossRef] [PubMed]
[42] Li, M.O. and Rudensky, A.Y. (2016) T Cell Receptor Signal-ling in the Control of Regulatory T Cell Differentiation and Function. Nature Reviews Immunology, 16, 220-233. [Google Scholar] [CrossRef] [PubMed]
[43] Zhang, Q., Chikina, M., Szymczak-Workman, A.L., et al. (2017) LAG3 Limits Regulatory T Cell Proliferation and Function in Autoimmune Diabetes. Science Immunology, 2, eaah4569. [Google Scholar] [CrossRef] [PubMed]
[44] Gagliani, N., Magnani, C.F., Huber, S., et al. (2013) Coexpres-sion of CD49b and LAG-3 Identifies Human and Mouse T Regulatory Type 1 Cells. Nature Medicine, 19, 739-746. [Google Scholar] [CrossRef] [PubMed]
[45] Okamura, T., Fujio, K., Shibuya, M., et al. (2009) CD4+CD25-LAG3+ Regulatory T Cells Controlled by the Transcription Factor Egr-2. Proceedings of the National Academy of Sciences of the United States of America, 106, 13974- 13979. [Google Scholar] [CrossRef] [PubMed]
[46] Okamura, T., Sumi-tomo, S., Morita, K., et al. (2015) TGF-β3-Expressing CD4+CD25(-)LAG3+ Regulatory T Cells Control Humoral Im-mune Responses. Nature Communications, 6, Article No. 6329. [Google Scholar] [CrossRef] [PubMed]
[47] Lino, A.C., Dang, V.D., Lampropoulou, V., et al. (2018) LAG-3 Inhib-itory Receptor Expression Identifies Immunosuppressive Natural Regulatory Plasma Cells. Immunity, 49, 120-133. [Google Scholar] [CrossRef] [PubMed]
[48] Ma, C., Sun, X., Shen, D., Sun, Y., Guan, N. and Qi, C. (2020) Ectopic Expression of LAG-3 in Non-Small-Cell Lung Cancer Cells and Its Clinical Significance. Journal of Clinical Laboratory Analysis, 34, e23244. [Google Scholar] [CrossRef] [PubMed]
[49] He, Y., Yu, H., Rozeboom, L., et al. (2017) LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. Journal of Thoracic Oncology, 12, 814-823. [Google Scholar] [CrossRef] [PubMed]
[50] He, Y., Rivard, C.J., Rozeboom, L., Yu, H., Ellison, K., Kowalew-ski, A., Zhou, C. and Hirsch, F.R. (2016) Lymphocyte-Activation Gene-3, an Important Immune Checkpoint in Cancer. Cancer Science, 107, 1193-1197. [Google Scholar] [CrossRef] [PubMed]
[51] Vilgelm, A.E., Johnson, D.B. and Richmond, A. (2016) Combinatorial Ap-proach to Cancer Immunotherapy: Strength in Numbers. Journal of Leukocyte Biology, 100, 275-290. [Google Scholar] [CrossRef] 

为你推荐